SCHEMBL6985160

SCHEMBL6985160

CCCC(CC(=O)N1CCN(c2cccc(Cl)c2)CC1)NC(=O)[C@H]1O[C@@H]1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 2/20 0.46
KDM4E B2RXH2 2/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
RECQL P46063 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTR1A P08908 3/20 0.45
HTR7 P34969 2/20 0.45
GRM5 P41594 1/20 0.43
AIMP2 Q13155 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6985573 0.91 CASP1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL6981304 0.90 CNR1 (0.44) MEN1KMT2ASMN1; SMN2HTR1AHTR7
SCHEMBL6981707 0.85 SMN1; SMN2 (0.43) MEN1KMT2AALDH1A1SMN1; SMN2TSHR
SCHEMBL6981146 0.84 ALDH1A1 (0.45) MEN1KMT2AALDH1A1SMN1; SMN2TSHR
SCHEMBL6984525 0.83 GFER (0.46) MEN1KMT2AALDH1A1TSHRKDM4E
SCHEMBL6985150 0.78 NPSR1 (0.50) MEN1KMT2AALDH1A1SMN1; SMN2TSHR
SCHEMBL6978571 0.77 KMT2A (0.44) MEN1KMT2AALDH1A1SMN1; SMN2TSHR
SCHEMBL6983402 0.74 NPC1 (0.54) MEN1KMT2AALDH1A1KDM4ENPSR1
SCHEMBL6979227 0.73 GAA (0.39) KMT2AALDH1A1SMN1; SMN2MAPK1NPSR1
SCHEMBL4776950 0.70 ALDH1A1 (0.73) MEN1KMT2AALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed